5Dickinson JM, Mitchison DA. In vitro activity of new rifamycins against fifampicin-resistance m. tuberculosis and MAIS-complex mycobacteria. Tubercle, 1987,68 : 177-182. 被引量：1
2Bonilla CA, Crossa A, Jave HO, Mitnick CD, Jamanea RB, Herrera C, Asencios L, Mendoza A, Bayona J, Zignol M, Jaramillo E. Management of extensively drug-resistant tuberculosis in Peru: cure is possible[J]. PLoS ONE, 2008,3(8) :e2957. 被引量：1
3Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri MV, Farnia P, Javanmard P, Mansouri D, Velayati AA. Outcome of treatment of MDR-TB patients with standardised regimens, Iran,2002--2006[J].Int J Tuberc Lung Dis, 2008, 12(7) :750--755. 被引量：1
4Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, Suo J, Lin TP. Outcome of pulmonary multidrug-resistant tubereulosis: a 6-yr follow-up study[J].Eur Respir J. 2006,28 (5) :980-985. 被引量：1
5WHO/IUATLD. Guidelines for surveillance of drug resistance in tuberculosis [J].Int J Tuberc Lung Dis, 1998, 2(1): 72-- 89. 被引量：1
6World Health Organization. Tuberculosis Control 2008 SURVEILLANCE PLANING FINACING: The global burden of TB:12--13. 被引量：1
7Shean KP, Willeox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, Wells CD, Hohz TH. Treatment outcome and follow-up of muhidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992--2002[J]. Int J Tubere Lung Dis,2008,12(10) : 1182-- 1189. 被引量：1
